Panelists discuss key findings from the KEYNOTE-A18 trial, which evaluated pembrolizumab in combination with chemoradiotherapy for high-risk locally advanced cervical cancer, highlighting the implications for treatment approaches in this patient population.
Read More
Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration
Panelists discuss recent data on various antibody-drug conjugates (ADCs) in ovarian cancer, including mirvetuximab soravtansine from trials like FORWARD II, MIRASOL, and PICCOLO; luveltamab tazevibulin and rinatabart sesutecan from STRO-002-GM1 and REFRαME-O1; and raludotatug deruxtecan from REJOICE-Ovarian01, highlighting the evolving role of these agents in the treatment landscape for ovarian cancer.
Read More
Use of Trastuzumab Deruxtecan in Ovarian Cancer
Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, its potential impact on treating advanced ovarian cancer given HER2 data, and how T-DXd may fit into the current treatment algorithm for ovarian cancer.
Read More
Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO trial on managing oligometastases or oligoprogression, and approaches to mitigate or manage common adverse events associated with PARPi maintenance therapy.
Read More
Emerging Combinations in Maintenance Therapy for Ovarian Cancer
Panelists discuss how emerging maintenance strategies for advanced/metastatic disease increasingly focus on novel combination approaches, including immunotherapy combinations with PARP inhibitors (rucaparib + nivolumab), anti-angiogenic agents (atezolizumab + bevacizumab), and dual targeted therapy (olaparib + cediranib), with ongoing evaluation of optimal patient selection and sequencing in the treatment paradigm.
Read More
Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer
Panelists explore emerging combination therapies in maintenance treatment for advanced ovarian cancer, including rucaparib + nivolumab; atezolizumab + bevacizumab; and olaparib + cediranib, also discussing how these strategies fit into the current treatment paradigm and in which patient populations they may be considered.
Read More
Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.
Read More
Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.
Read More
Evolving Treatment Strategies for Recurrent Low-Grade Serous Ovarian Cancer
October 27th 2023Expert oncologist Premal Thaker, MD, MS, reviews the current treatment landscape for recurrent low-grade serous ovarian cancer and considers the respective roles of various targeted agents in this setting.
Read More
Cervical Cancer Management: Looking Toward the Future of Care
Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
Read More
Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use
Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.
Read More
Metastatic Cervical Cancer: ADC Adverse Event Management
Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.
Read More
Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer
Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.
Read More
Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line
Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
Read More
Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer
An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
Read More
Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer
Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
Read More
Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826
Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.
Read More
KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer
Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.
Read More
Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer
Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.
Read More
Ongoing Clinical Trials in Locally Advanced Cervical Cancer
Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.
Read More
Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial
Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.
Read More
Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy
Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.
Read More
What is the Current Role of Biomarker Testing in Cervical Cancer?
The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.
Read More
Role of HPV Vaccination and Screening to Prevent Cervical Cancer
A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.
Read More
Understanding the Biology and Staging of Cervical Cancer
Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.
Read More